Your browser doesn't support javascript.
loading
Oxime derivatives related to AP18: Agonists and antagonists of the TRPA1 receptor.
Defalco, Jeff; Steiger, Daniel; Gustafson, Amy; Emerling, Daniel E; Kelly, Michael G; Duncton, Matthew A J.
Affiliation
  • Defalco J; Renovis, Inc. (a wholly-owned subsidiary of Evotec AG), Two Corporate Drive, South San Francisco, CA 94080, USA. jeff.defalco@gmail.com
Bioorg Med Chem Lett ; 20(1): 276-9, 2010 Jan 01.
Article in En | MEDLINE | ID: mdl-19945872
AP18 1 was recently disclosed as an antagonist of the TRPA1 receptor by the research group of Patapoutian. However, no detailed structure-activity relationships around 1 have been disclosed. Thus, a small number of oximes related to AP18 were examined in order to characterize the determinants of TRPA1 activity. Congeners of AP18 were found to possess both agonist and antagonist activity, suggesting that AP18 may behave as a covalent antagonist of the TRPA1 ion-channel.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Oximes / Transient Receptor Potential Channels / Nerve Tissue Proteins Limits: Humans Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 2010 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Oximes / Transient Receptor Potential Channels / Nerve Tissue Proteins Limits: Humans Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 2010 Type: Article Affiliation country: United States